Immunological markers in adult patients with epilepsy
|Organizations:||University of Oulu, Faculty of Medicine, Department of Neurology
Seinäjoki Central Hospital, Department of Neurology
University of Tampere, School of Public Health
|Online Access:||PDF Full Text (PDF, 0.9 MB)|
|Persistent link:|| http://urn.fi/urn:isbn:9514276752
|Publish Date:|| 2005-04-19
|Thesis type:||Doctoral Dissertation
|Defence Note:||Academic Dissertation to be presented with the assent of the Faculty of Medicine, University of Oulu, for public discussion in the Auditorium 8 of Oulu University Hospital, on April 29th, 2005, at 12 noon
Docent Aki Hietaharju
Docent Aarne Ylinen
Increased prevalence of anticardiolipin antibodies (aCL) and antinuclear antibodies (ANA) and changes in serum immunoglobulin concentrations have been reported in patients with epilepsy.
The purpose of this study was to determine the presence of aCL, ANA, anti-B2 glycoprotein I -antibodies (anti-B2-GPI), antimitochondrial antibodies (AMA), immunoglobulin A, G and M serum concentrations and the presence of IgA and IgG class antigliadin antibodies (AGAbA and AGAbG), transglutaminase antibodies (tTGAbA) and antiendomysial antibodies (EMA) in a cohort of 1386 adult patients treated for epilepsy in the Oulu University Central Hospital during the years 1996–7 and in a reference population obtained from the Population Register Centre and matched for age, gender and municipality of residence. The effects of co-morbidity, medications, age, gender and different epilepsy attributes on the occurrence of the immunological parameters studied as well as the possible interrelations of these parameters were studied.
There was no difference in the presence of aCL or ANA between the patients and the reference subjects. In patients, aCL were associated with long duration of epilepsy and poor seizure control. Low IgA serum concentrations were more common in patients with epilepsy, particularly those using phenytoin. Unspecific AMA were more common among the epilepsy patients. The prevalence of coeliac disease (CD)-related antibodies was similar in patients with epilepsy and in the reference population. AGAbA were associated with primary generalised epilepsy. No significant interrelations between the immunological markers were found. These findings suggest that patients with epilepsy do not have an increased prevalence of autoantibodies as a result of their disease. Various factors such as genetic traits and epilepsy attributes may independently affect the presence of each individual immunological marker.
Acta Universitatis Ouluensis. D, Medica
|Copyright information:||This publication is copyrighted. You may download, display and print it for your own personal use. Commercial use is prohibited.|